Update shared on05 Sep 2025
With no meaningful change in either the discount rate or forward P/E multiple, analysts have maintained SRF's fair value estimate at ₹3105.
What's in the News
- SRF Limited has entered into strategic agreements with The Chemours Company to strengthen Chemours' global supply chain for fluoropolymers and fluoroelastomers, leveraging SRF's manufacturing capabilities.
- The collaboration provides Chemours with increased operational flexibility and reliable supply for customers across industries without requiring upfront capital investment.
- SRF's board will meet to consider unaudited financial results for the quarter ended June 2025, declaration of a 1st interim dividend for FY 2025-26, and enabling issuance of non-convertible debentures up to INR 7,500 million.
Valuation Changes
Summary of Valuation Changes for SRF
- The Consensus Analyst Price Target remained effectively unchanged, at ₹3105.
- The Discount Rate for SRF remained effectively unchanged, moving only marginally from 13.60% to 13.61%.
- The Future P/E for SRF remained effectively unchanged, moving only marginally from 42.60x to 42.62x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.